|
gene editing |
5 |
|
bcl11b |
3 |
|
crispr/cas9 |
3 |
|
expanded potential |
3 |
|
gain of function |
3 |
|
immunodeficiency |
3 |
|
inborn errors of immunity |
3 |
|
janus activating kinase (jak) inhibitor |
3 |
|
model |
3 |
|
personalized |
3 |
|
phosphorylation |
3 |
|
signal transducer and activator of transcription 1 (stat1) |
3 |
|
stem cell |
3 |
|
biotechnology |
2 |
|
chimera |
2 |
|
dentate gyrus |
2 |
|
embryo |
2 |
|
gene expression |
2 |
|
hippocampus |
2 |
|
immunotherapy |
2 |
|
reprogramming |
2 |
|
transcription factor |
2 |
|
129sv |
1 |
|
2c like cell |
1 |
|
adult neurogenesis |
1 |
|
allograft |
1 |
|
angptl7 |
1 |
|
anti-pd-l1/pd-1 monoclonal antibody |
1 |
|
apoptosis |
1 |
|
b-all |
1 |
|
bac library |
1 |
|
bcl11a |
1 |
|
bcl11a (ctip1) |
1 |
|
bcl11b/ctip2 |
1 |
|
bovine |
1 |
|
bovine ipscs |
1 |
|
cancer |
1 |
|
cancer models |
1 |
|
car |
1 |
|
car t |
1 |
|
car t cell |
1 |
|
cas9 |
1 |
|
cd19 |
1 |
|
cd4+ t cell |
1 |
|
cell differentiation |
1 |
|
cell metabolism |
1 |
|
cell population |
1 |
|
cell structure |
1 |
|
cell therapy |
1 |
|
cellular heterogeneity |
1 |
|
chromosome engineering |
1 |
|
commitment |
1 |
|
conditional knockout |
1 |
|
cre-loxp recombination |
1 |
|
crispr |
1 |
|
devbio |
1 |
|
e. coli |
1 |
|
e2a |
1 |
|
embryonic stem cell |
1 |
|
embryonic stem cells |
1 |
|
enhancer region |
1 |
|
epiblast stem cells |
1 |
|
epigenetics |
1 |
|
es cell |
1 |
|
expanded potential stem cell |
1 |
|
expanded potential stem cells |
1 |
|
expansion |
1 |
|
female |
1 |
|
forward genetic screen |
1 |
|
fukutin-related protein |
1 |
|
gene |
1 |
|
gene targeting |
1 |
|
genetic modified mice |
1 |
|
genetics |
1 |
|
genomics |
1 |
|
haematopoiesis |
1 |
|
hematopoietic stem cell |
1 |
|
hematopoietic stem cells |
1 |
|
hepatocellular carcinoma |
1 |
|
heterogeneity |
1 |
|
high-throughput screening |
1 |
|
hinge domain |
1 |
|
hit and run |
1 |
|
homing |
1 |
|
human-induced pluripotent stem cells |
1 |
|
humanized mice |
1 |
|
humanized mouse model |
1 |
|
humdisease |
1 |
|
identity |
1 |
|
immune cell development |
1 |
|
induced pluripotent stem cell |
1 |
|
induced pluripotent stem cells |
1 |
|
inkt cell selection |
1 |
|
innate lymphoid cells |
1 |
|
insertional mutagenesis |
1 |
|
invariant natural killer t-cell development |
1 |
|
klf4 |
1 |
|
knock-in |
1 |
|
knockout-mice |
1 |
|
leukemia |
1 |
|
leukemia stem cell |
1 |
|
liver receptor homolog-1 |
1 |
|
lscc |
1 |
|
lymphopoiesis |
1 |
|
lysosomal storage disorder |
1 |
|
mdm2 |
1 |
|
mesothelin |
1 |
|
mossy fiber boutons |
1 |
|
mouse |
1 |
|
mouse genome |
1 |
|
muc1 |
1 |
|
mutagenesis |
1 |
|
natural killer |
1 |
|
naã¯ve pluripotency |
1 |
|
neurogenesis |
1 |
|
neuronal differentiation |
1 |
|
non-small-cell lung cancer |
1 |
|
non-small-cell-lung cancer |
1 |
|
notch-delta signaling |
1 |
|
notch1 |
1 |
|
nuclear reprogramming |
1 |
|
nuclear transfer |
1 |
|
patient-derived xenograft |
1 |
|
patient-derived-xenograft |
1 |
|
pd-1 |
1 |
|
pdx |
1 |
|
piggybac |
1 |
|
piggybac transposition |
1 |
|
piggybac transposon |
1 |
|
pluripotency |
1 |
|
porcine |
1 |
|
prdm16 |
1 |
|
primed pluripotency |
1 |
|
prognosis |
1 |
|
proto-oncogene |
1 |
|
psca |
1 |
|
pu.1 |
1 |
|
qiseq |
1 |
|
quiescence |
1 |
|
rareoct |
1 |
|
recombineering |
1 |
|
regulatory networks |
1 |
|
repopulation |
1 |
|
retinoic acid receptor gamma |
1 |
|
retinoic acid receptors |
1 |
|
retrovital mutagenesis |
1 |
|
scrna-seq |
1 |
|
sh-ipsc |
1 |
|
single-cell |
1 |
|
sleeping beauty |
1 |
|
spatial memory |
1 |
|
spinal cord |
1 |
|
stella |
1 |
|
synapses |
1 |
|
t cell |
1 |
|
t cell development |
1 |
|
t cells |
1 |
|
t-all |
1 |
|
transcription activator-like effectors |
1 |
|
transcriptional control of inkt lineage |
1 |
|
transgenics |
1 |
|
transposition |
1 |
|
transposon |
1 |
|
tumor |
1 |
|
validation |
1 |
|
vector |
1 |
|
xenograft |
1 |
|
xenografts |
1 |
|
î²-catenin |
1 |
|
α-dystroglycan |
1 |
